Aldeyra Therapeutics is a leading brand dedicated to inventing, developing, and commercializing next-generation medicines that effectively treat immune-mediated diseases. With a strong focus on improving the lives of patients, their pipeline consists of cutting-edge drug candidates that target inflammatory cells associated with ocular and systemic conditions not adequately addressed by current treatments. By leveraging innovative mechanisms of action, Aldeyra aims to restore balance and provide patients with better treatment options for immune-mediated diseases.

Currently, their investigational therapies for dry eye disease, allergic conjunctivitis, and proliferative vitreoretinopathy are in Phase 3 trials, bringing them closer to their goal of offering novel medicines in these areas. With a therapeutic focus on immune-mediated diseases with high unmet need, Aldeyra is developing therapies to address conditions like dry eye disease, allergic conjunctivitis, and proliferative vitreoretinopathy. Their lead product candidates include Reproxalap for Dry Eye Disease, Reproxalap for Allergic Conjunctivitis, and ADX-2191 for PVR, offering hope to millions of patients suffering from these conditions.

Discover more about Aldeyra's groundbreaking pipeline and their mission to improve patient outcomes